Giá của Hansa Biopharma AB là bao nhiêu (HNSBF)

Giá của Hansa Biopharma AB (HNSBF) là $3.70

Mũ thị trường của Hansa Biopharma AB là gì (HNSBF)

Giới hạn thị trường của Hansa Biopharma AB (HNSBF) là $369.01M

Hansa Biopharma AB (HNSBF) Tỷ Suất Cổ Tức

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Năm	Lợi suất cổ tức	Thay đổi
Không đủ dữ liệu cho ngày được cung cấp.

Năm

Lợi suất cổ tức

Thay đổi

Không đủ dữ liệu cho ngày được cung cấp.

Công ty	Lợi suất cổ tức	Quốc gia
Royalty Pharma plc RPRX.US	1.51%	US
Swedish Orphan Biovitrum AB SOBI.ST	0.00%	SE
Ipsen S.A. IPN.PA	0.00%	FR
Recordati Industria Chimica e Farmaceutica S.p.A. REC.MI	0.00%	IT
Corcept Therapeutics Incorporated CORT.US	0.00%	US

Công ty

Lợi suất cổ tức

Quốc gia